Cargando…

Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease

Platelets play a significant role in atherothrombosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is critically involved in the regulation of LDL metabolism and interacts with platelet function. The effect of PCSK9 in platelet function is poorly understood. The authors of this article sou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersen-Uribe, Álvaro, Kremser, Marcel, Rohlfing, Anne-Katrin, Castor, Tatsiana, Kolb, Kyra, Dicenta, Valerie, Emschermann, Frederic, Li, Bo, Borst, Oliver, Rath, Dominik, Müller, Karin Anne Lydia, Gawaz, Meinrad Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538687/ https://www.ncbi.nlm.nih.gov/pubmed/34681838 http://dx.doi.org/10.3390/ijms222011179

Ejemplares similares

Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation
por: Nestele, Jeremy A., et al.
Publicado: (2021)

Large-scale lipidomics profiling reveals characteristic lipid signatures associated with an increased cardiovascular risk
por: Harm, Tobias, et al.
Publicado: (2023)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Platelet SR-PSOX/CXCL16–CXCR6 Axis Influences Thrombotic Propensity and Prognosis in Coronary Artery Disease
por: Guan, Tianyun, et al.
Publicado: (2022)

Risk assessment in COVID‐19: Prognostic importance of cardiovascular parameters
por: Zdanyte, Monika, et al.
Publicado: (2022)

COVID-19 versus seasonal influenza: myocardial injury and prognostic importance
por: Mizera, Lars, et al.
Publicado: (2022)

ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury
por: Rohlfing, Anne-Katrin, et al.
Publicado: (2022)

Platelet Expression of Stromal Cell-Derived Factor-1 Is Associated with the Degree of Valvular Aortic Stenosis
por: Wurster, Thomas, et al.
Publicado: (2014)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection
por: Rath, Dominik, et al.
Publicado: (2020)

Effect of Oxidized LDL on Platelet Shape, Spreading, and Migration Investigated with Deep Learning Platelet Morphometry
por: Seifert, Jan, et al.
Publicado: (2021)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Deceleration capacity is associated with acute respiratory distress syndrome in COVID-19
por: Mizera, Lars, et al.
Publicado: (2021)

Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
por: Jourdi, Georges, et al.
Publicado: (2022)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Homophilic Interaction Between Transmembrane-JAM-A and Soluble JAM-A Regulates Thrombo-Inflammation: Implications for Coronary Artery Disease
por: Rath, Dominik, et al.
Publicado: (2022)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

Impaired Myocardial Function Is Prognostic for Severe Respiratory Failure in the Course of COVID-19 Infection
por: Petersen-Uribe, Alvaro, et al.
Publicado: (2021)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Antiplatelet combinations for prevention of atherothrombotic events
por: Bollati, Mario, et al.
Publicado: (2011)

Novel Antiplatelet Therapies for Atherothrombotic Diseases
por: Majithia, Arjun, et al.
Publicado: (2019)

Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk
por: Murphy, Andrew J., et al.
Publicado: (2022)

Unexplored Roles of Erythrocytes in Atherothrombotic Stroke
por: Papadopoulos, Charalampos, et al.
Publicado: (2023)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
por: Faraj, May
Publicado: (2020)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study
por: Reuwer, Anne Q., et al.
Publicado: (2011)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

Interventional Removal of LV Thrombus in a Patient With Cardiogenic Shock and Transitory Ischemic Attack
por: Gawaz, Meinrad Paul, et al.
Publicado: (2023)

Environmental noise exposure is associated with atherothrombotic risk
por: Koczorowski, Magali, et al.
Publicado: (2022)

Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases
por: Petrucci, Giovanna, et al.
Publicado: (2022)

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
por: Jourdi, Georges, et al.
Publicado: (2022)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
por: Duellman, Sarah J., et al.
Publicado: (2017)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
por: Benn, Marianne, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_50ublur5craf6eh2al5l5dt6qk